The therapeutic armamentarium for hemophilia A and B continues to expand with new and emerging non-factor alternatives and factor mimetics. These therapies can improve efficacy, provide durable hemostasis restoration, and help ensure safety in appropriate patients. Such agents include anti-tissue factor pathway inhibitors (TFPIs) and FVIII mimetics representing contemporary approaches to care that have also led to new pathways and assays for clinical and laboratory monitoring. In this CME Outfitters live activity, experts in hemophilia, including a patient who has lived with the disorder for many years, discuss the role of these newer therapies, how they work, and how to implement them in practice to improve quality of care and outcomes. A focused exercise in shared decision making keeps the conversation grounded in counseling and care and includes both clinician and patient perspectives.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com
- Start Date: 2024-04-05 05:00:00
- End Date: 2024-04-05 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Novo Nordisk (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Live Course
- CME Finder Type: Conference
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Internal Medicine